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ABSTRACT
Sporadic CJD is a rare and fatal spongiform encephalopathy characterized by rapidly progressive dementia and 
myoclonus. It is a rare cause of dementia with an estimated incidence of the disease in one patient per million per 
year worldwide, however, no data is available for Pakistan. As it is a rare cause of dementia, so rarely considered in 
differential diagnosis of rapidly progressive dementia.
C A S E  R E P O R T
INTRODUCTION: CJD is a rare degenerative brain 
disorder which is almost always fatal, it is characterized 
by progressive brain dysfunction.1 CJD falls into four 
categories, sporadic, iatrogenic, familial and variant.2 
Sporadic CJD is most common and accounts for 85% 
of all cases. It occurs worldwide and its incidence 
ranges from 0.5 to 1.5 cases per million per year. Of 
the remaining 15% of cases, 10 percent (%) is familial 
and iatrogenic and variant comprise 2 to 5 percent. 
CJD should be suspected in patients who presented 
with cerebellar signs, myoclonic jerks, and rapidly 
progressive dementia. However, these symptoms and 
signs are usually preceded by Psychiatric symptoms, 
which could be easily ignored.
Case Report:
A 75 years old man, with no previous history any 
significant medical or surgical disease, presented with 
two months history of dementia that started with 
delusion of persecution followed by worsening mobility, 
lack of coordination and cognitive issues. Over a course 
of four weeks he was not able to mobilize, started 
having visual hallucination, and myoclonic jerks. On 
examination patient was non-communicative, drowsy 
and had myoclonic jerks. Primitive reflexes were 
present in the form of palmer grasp and snout reflexes. 
He had moderate to severe axial and cogwheel rigidity 
in both upper and lower limbs. Reflexes were 
symmetrically brisk and plantars were bilaterally up 
going. Patient was admitted in neurology unit for further 
investigations. Base line blood tests were performed 
with normal results of liver and renal function tests, 
complete blood count, ESR, Serum Electrolytes. MRI 
brain showed gyriform cortical hyperintensity in both 
cerebral hemispheres and restricted diffusion in the 
same areas with corresponding low ADC values (cortical 
ribboning). Restricted diffusion was also observed in 
the caudate head bilaterally (figures 1a and 1b). EEG 
showed slow background rhythm with periodic sharp 
wave complexes with a frequency of 1-2 hz (figure.2). 
MRI-CJD consortium diagnostic criteria was applied to 
diagnose the case of sporadic CJD (Table.1)3. Patient 
remain admitted in our unit for three days, after 
excluding all the treatable causes, patient’s attendants 
were counseled about the prognosis of disease and 
transmission of this fatal disorder.
Discussion:
CJD is prion disease that is transmittable. Diagnosis of 
CJD in early stages is fairly challenging due to very low 
incidence and high variability of initial presenting 
symptoms. Other rapidly progressive dementias can 
resemble sCJD due to overlapping of clinical 
presentation, and thus make the diagnosis of sCJD 
difficult especially in the early stage of presentation. 
The predominance of psychiatric symptoms and/or 
extrapyramidal usually mask the early onset of 
dementia. Nearly twenty six percent patients first 
present with “behavioral symptoms” such as agitation, 
irritability and depression initially.4 Myoclonus may be 
absent in early stages of disease and may appear in 
advanced stages of disease.  Akinetic mutism is usually 
manifested at the end of disease.
The definitive neuropathological diagnosis of sCJD, 
which is not feasible in clinical practice, depends on 
biopsy/autopsy characterized by loss of neuron, gliosis, 
spongiform, degeneration or the presence of 
protease-resistance prion protein (PrPSc) on 
histolopathology of brain tissue. Center of disease 
control (CDC) has proposed a probable diagnosis of 
sCJD based on the following four criteria. 1) Progressive 
dementia 2) at least two out of the following four 
clinical features: a)Myoclonus b) Visual or cerebellar 
signs  c) Pyramidal/extrapyramidal signs d)Akinetic 
mutism. 3) typical EEG and/or positive 14-3-3 CSF 
assay and/or MRI high signal abnormalities on DWI or 
FLAIR. 4) Unremarkable alternative diagnosis on 
dementia screening. 5
DWI and FLAIR imaging of brain MRI can be utilized for 
the early diagnosis of sCJD with a sensitivity of 91% 
and specificity of 95%.6 MRI shows cortical signal 
increase and hyperintensities in the basal ganglia and 
thalamus.7 Hyperintensities in DWI greater than FLAIR 
imaging and restricted diffusion are more common in 
sCJD than in any other rapidly progressive dementia 
disease which may facilitate differentiating sCJD from 
other prion disease. EEG can be used as an adjunctive 
non-invasive method to diagnose sCJD. The periodic 
sharp wave complexes (PSWCs) in the EEG are typical 
for sCJD, however in early stages of the disease there 
may only be nonspecific findings such as diffuse 
slowing and frontal rhythmic delta activity (FIRDA) and 
non-convulsive status 8 The sensitivity and specificity of 
periodic sharp wave complexes on EEG is 67 % and 86 
% respectively.9 CSF 14-3-3 protien analysis has a 
relatively high sensitivity but a moderate specificity. One 
study showed that CSF 14-3-3 protein possessed a 
sensitivity of 97% and a specificity of 87% in 
diagnosing sCJD.10
We could not perform the CSF 14-3-3 protein analysis 
because of the lack of the availability of the test at our 
country and higher chance of transmission during the 
intervention. Diagnosis can only be confirmed by 
histological examination of brain tissue obtained either 
by the brain biopsy or after autopsy which was not 
possible in our set-up.
Conclusion:
sCJD is a fatal disorder and it is transmittable from 
person to person , therefore unnecessary interventions 
should always be avoided. Although a rare disease, it 
should be considered in the differential diagnosis of 
rapidly progressive dementia along with other disorders.
 
(FIGURE.1a DWI)
INCREASE UPTAKE IN CORTICAL AND BASAL 
GANGLION  
(FIGURE.1b, ADC)
LOW UPTAKE ON ADC IN THE FRONTOPARITAL 
CORTEX 
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absent in early stages of disease and may appear in 
advanced stages of disease.  Akinetic mutism is usually 
manifested at the end of disease.
The definitive neuropathological diagnosis of sCJD, 
which is not feasible in clinical practice, depends on 
biopsy/autopsy characterized by loss of neuron, gliosis, 
spongiform, degeneration or the presence of 
protease-resistance prion protein (PrPSc) on 
histolopathology of brain tissue. Center of disease 
control (CDC) has proposed a probable diagnosis of 
sCJD based on the following four criteria. 1) Progressive 
dementia 2) at least two out of the following four 
clinical features: a)Myoclonus b) Visual or cerebellar 
signs  c) Pyramidal/extrapyramidal signs d)Akinetic 
mutism. 3) typical EEG and/or positive 14-3-3 CSF 
assay and/or MRI high signal abnormalities on DWI or 
FLAIR. 4) Unremarkable alternative diagnosis on 
dementia screening. 5
DWI and FLAIR imaging of brain MRI can be utilized for 
the early diagnosis of sCJD with a sensitivity of 91% 
and specificity of 95%.6 MRI shows cortical signal 
increase and hyperintensities in the basal ganglia and 
thalamus.7 Hyperintensities in DWI greater than FLAIR 
imaging and restricted diffusion are more common in 
sCJD than in any other rapidly progressive dementia 
disease which may facilitate differentiating sCJD from 
other prion disease. EEG can be used as an adjunctive 
non-invasive method to diagnose sCJD. The periodic 
sharp wave complexes (PSWCs) in the EEG are typical 
for sCJD, however in early stages of the disease there 
may only be nonspecific findings such as diffuse 
slowing and frontal rhythmic delta activity (FIRDA) and 
non-convulsive status 8 The sensitivity and specificity of 
periodic sharp wave complexes on EEG is 67 % and 86 
% respectively.9 CSF 14-3-3 protien analysis has a 
relatively high sensitivity but a moderate specificity. One 
study showed that CSF 14-3-3 protein possessed a 
sensitivity of 97% and a specificity of 87% in 
diagnosing sCJD.10
We could not perform the CSF 14-3-3 protein analysis 
because of the lack of the availability of the test at our 
country and higher chance of transmission during the 
intervention. Diagnosis can only be confirmed by 
histological examination of brain tissue obtained either 
by the brain biopsy or after autopsy which was not 
possible in our set-up.
Conclusion:
sCJD is a fatal disorder and it is transmittable from 
person to person , therefore unnecessary interventions 
should always be avoided. Although a rare disease, it 
should be considered in the differential diagnosis of 
rapidly progressive dementia along with other disorders.
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which is not feasible in clinical practice, depends on 
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spongiform, degeneration or the presence of 
protease-resistance prion protein (PrPSc) on 
histolopathology of brain tissue. Center of disease 
control (CDC) has proposed a probable diagnosis of 
sCJD based on the following four criteria. 1) Progressive 
dementia 2) at least two out of the following four 
clinical features: a)Myoclonus b) Visual or cerebellar 
signs  c) Pyramidal/extrapyramidal signs d)Akinetic 
mutism. 3) typical EEG and/or positive 14-3-3 CSF 
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FLAIR. 4) Unremarkable alternative diagnosis on 
dementia screening. 5
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the early diagnosis of sCJD with a sensitivity of 91% 
and specificity of 95%.6 MRI shows cortical signal 
increase and hyperintensities in the basal ganglia and 
thalamus.7 Hyperintensities in DWI greater than FLAIR 
imaging and restricted diffusion are more common in 
sCJD than in any other rapidly progressive dementia 
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other prion disease. EEG can be used as an adjunctive 
non-invasive method to diagnose sCJD. The periodic 
sharp wave complexes (PSWCs) in the EEG are typical 
for sCJD, however in early stages of the disease there 
may only be nonspecific findings such as diffuse 
slowing and frontal rhythmic delta activity (FIRDA) and 
non-convulsive status 8 The sensitivity and specificity of 
periodic sharp wave complexes on EEG is 67 % and 86 
% respectively.9 CSF 14-3-3 protien analysis has a 
relatively high sensitivity but a moderate specificity. One 
study showed that CSF 14-3-3 protein possessed a 
sensitivity of 97% and a specificity of 87% in 
diagnosing sCJD.10
We could not perform the CSF 14-3-3 protein analysis 
because of the lack of the availability of the test at our 
country and higher chance of transmission during the 
intervention. Diagnosis can only be confirmed by 
histological examination of brain tissue obtained either 
by the brain biopsy or after autopsy which was not 
possible in our set-up.
Conclusion:
sCJD is a fatal disorder and it is transmittable from 
person to person , therefore unnecessary interventions 
should always be avoided. Although a rare disease, it 
should be considered in the differential diagnosis of 
rapidly progressive dementia along with other disorders.
 
(FIGURE.1a DWI)
INCREASE UPTAKE IN CORTICAL AND BASAL 
GANGLION  
(FIGURE.1b, ADC)
LOW UPTAKE ON ADC IN THE FRONTOPARITAL 
CORTEX 
REFERENCES
1. Johnson RT, Gibbs Jr CJ. Creutzfeldt–Jakob disease 
and related transmissible spongiform 
encephalopathies. N Engl J Med. 
1998;339(27):1994-2004.
2. Head MW, Ritchie D, Smith N, McLoughlin V, Nailon 
W, Samad S, et al. Peripheral tissue involvement in 
sporadic, iatrogenic, and variant Creutzfeldt-Jakob 
disease: an immunohistochemical, quantitative, 
and biochemical study. Am J Pathol. 
2004;164(1):143-53.
3. Zerr I, Kallenberg K, Summers DM, Romero C, 
Taratuto A, Heinemann U, et al. Updated clinical 
  diagnostic criteria for sporadic Creutzfeldt-Jakob 
disease. Brain. 2009;132(10):2659-68
4. Wall CA, Rummans TA, Aksamit AJ, Krahn LE, 
Pankratz VS. Psychiatric manifestations of 
Creutzfeldt-Jakob disease: a 25-year analysis. J 
Neuropsychiatry Clin Neurosci. 2005;17(4):489.
5.Kojima G, Tatsuno BK, Inaba M, Velligas S, Masaki K, 
Liow KK. Creutzfeldt-Jakob disease: a case report 
and differential diagnoses. Hawaii J Med Public 
Health. 2013;72(4):136.
6. Young GS, Geschwind MD, Fischbein NJ, Martindale 
JL, Henry RG, Liu S, et al. Diffusion-weighted and 
fluid-attenuated inversion recovery imaging in 
Creutzfeldt-Jakob disease: high sensitivity and 
specificity for diagnosis.. AJNR Am J Neuroradiol. 
2005;26(6):1551-62.
7. Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, 
Summers DM, Almonti S, et al. MRI lesion profiles 
in sporadic Creutzfeldt–Jakob disease. Neurology. 
2009;72(23):1994-2001.
3 3P A K I S T A N  J O U R N A L  O F  N E U R O L O G I C A L  S C I E N C E S V O L .  1 3  ( 4 )   O C T- D E C E M B E R  2 0 1 8
 
8. Wieser HG, Schindler K, Zumsteg D. EEG in 
Creutzfeldt–Jakob disease. Clin Neurophysiol. 
2006;117(5):935-51.
9. Steinhoff BJ, Racker S, Herrendorf G, Poser S, 
Grosche S, Zerr I, et al. Accuracy and reliability of 
periodic sharp wave complexes in 
Creutzfeldt-Jakob disease. Arch Neurol. 
1996;53(2):162-6.
10. Lemstra AW, Van Meegen MT, Vreyling JP, Meijerink 
PH, Jansen GH, Bulk S, et al. 14-3-3 testing in 
diagnosing Creutzfeldt–Jakob disease A 
prospective study in 112 patients. Neurology. 
2000;55(4):514-6.
c a l c i n o s i s . 
https://www.orpha.net/consor/cgi-bin/OC_Exp.php
?Lng=GB&Expert=1980 (accessed 23 July 
2018).
4. Manyam BV, Walters AS, Narla KR. Bilateral 
striopallidodentate calcinosis: clinical 
characteristics of patients seen in a registry.. 
Movement Disorders: official journal of the 
movement disorder society 2001; 16(2): . 
https://www.ncbi.nlm.nih.gov/pubmed/11295778
# (accessed 23 July 2018).
5. Ellie E, Julien J, Ferrer X. Familial idiopathic 
striopallidodentate calcifications. Neurology 1989; 
39(3): . 
https://www.ncbi.nlm.nih.gov/pubmed/2927646 
(accessed 23 July 2018).
6. Geschwind DH, Loginov M, Stern JM.. Identification 
of a locus on chromosome 14q for idiopathic basal 
ganglia calcification (Fahr disease).. American 
Journal of Human Genetics 1999; 65(3): . 
https://www.ncbi.nlm.nih.gov/pubmed/10441584 
(accessed 23 July 2018).
7. Dai X, Gao Y, Xu Z, Cui X, Liu J, Li Y, Xu H, Liu M, 
Wang QK, Liu JY.. Identification of a novel genetic 
locus on chromosome 8p21.1-q11.23 for 
idiopathic basal ganglia calcification.. American 
Journal of Medical genetics. Part B, 
Neuropsychiatric genetics: the official publication 
of the international society of psychiatric genetics 
5 October 2010; 153B(7): . 
https://www.ncbi.nlm.nih.gov/pubmed/20552677 
(accessed 23 July 2018).
8. Volpato CB, De Grandi A, Buffone E, Facheris M, 
Gebert U, Schifferle G, et al. 2q37 as a 
susceptibility locus for idiopathic basal ganglia 
calcification (IBGC) in a large South Tyrolean 
family.. Journal of molecular neuroscience 2009; 
39(3): . 
https://www.ncbi.nlm.nih.gov/pubmed/19757205 
(accessed 24 July 2018).
9. ShafaqSaleem, Hafiz Muhammad Aslam, Maheen 
Anwar, Shahzad Anwar, Maria Saleem, 
AnumSaleem, et al. Fahr’s syndrome: literature 
review of current evidence. Orphanet Journal of 
rare diseases 2013; 8(): . 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38
53434/#B10 (accessed 24 July 2018).
10. Malathi Latha Perugula, MD and Steven Lippmann, 
MD. Fahr’s Disease or Fahr’s Syndrome?. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC50
22990/ (accessed 10 December 2018).
Table-1 
3MRI-CJD CONSORTIUM DIAGNOSTIC CRITERIA (2009) 
A)! CLINICAL SIGNS 
1.! Dementia 
2.! Cerebellar or Visual signs 
3.! Pyramidal or extra-pyramidal signs  
4.! Akinetic mutism 
B)! LABORTOARY TESTS  
1.! EEG: Periodic sharp wave complexes 
2.! CSF: Positive 14-3-3 proteins in patient with a disease duration of less than 2 years  
3.! MRI: high signal abnormalities in caudate nucleus and putamen or at least two cortical regions 
(temporal-parietal-occipital) either on DWI or FLAIR  
Probable sCJD 
 
 at least 2 of A + at least 1 of B 
Possible sCJD 
 
at least 2 of A + duration < 2 years 
 
 
(FIGURE.2) POSITIVE SHARP WAVE COMPLEXES OF 1-2 HZ ON EEG
absent in early stages of disease and may appear in 
advanced stages of disease.  Akinetic mutism is usually 
manifested at the end of disease.
The definitive neuropathological diagnosis of sCJD, 
which is not feasible in clinical practice, depends on 
biopsy/autopsy characterized by loss of neuron, gliosis, 
spongiform, degeneration or the presence of 
protease-resistance prion protein (PrPSc) on 
histolopathology of brain tissue. Center of disease 
control (CDC) has proposed a probable diagnosis of 
sCJD based on the following four criteria. 1) Progressive 
dementia 2) at least two out of the following four 
clinical features: a)Myoclonus b) Visual or cerebellar 
signs  c) Pyramidal/extrapyramidal signs d)Akinetic 
mutism. 3) typical EEG and/or positive 14-3-3 CSF 
assay and/or MRI high signal abnormalities on DWI or 
FLAIR. 4) Unremarkable alternative diagnosis on 
dementia screening. 5
DWI and FLAIR imaging of brain MRI can be utilized for 
the early diagnosis of sCJD with a sensitivity of 91% 
and specificity of 95%.6 MRI shows cortical signal 
increase and hyperintensities in the basal ganglia and 
thalamus.7 Hyperintensities in DWI greater than FLAIR 
imaging and restricted diffusion are more common in 
sCJD than in any other rapidly progressive dementia 
disease which may facilitate differentiating sCJD from 
other prion disease. EEG can be used as an adjunctive 
non-invasive method to diagnose sCJD. The periodic 
sharp wave complexes (PSWCs) in the EEG are typical 
for sCJD, however in early stages of the disease there 
may only be nonspecific findings such as diffuse 
slowing and frontal rhythmic delta activity (FIRDA) and 
non-convulsive status 8 The sensitivity and specificity of 
periodic sharp wave complexes on EEG is 67 % and 86 
% respectively.9 CSF 14-3-3 protien analysis has a 
relatively high sensitivity but a moderate specificity. One 
study showed that CSF 14-3-3 protein possessed a 
sensitivity of 97% and a specificity of 87% in 
diagnosing sCJD.10
We could not perform the CSF 14-3-3 protein analysis 
because of the lack of the availability of the test at our 
country and higher chance of transmission during the 
intervention. Diagnosis can only be confirmed by 
histological examination of brain tissue obtained either 
by the brain biopsy or after autopsy which was not 
possible in our set-up.
Conclusion:
sCJD is a fatal disorder and it is transmittable from 
person to person , therefore unnecessary interventions 
should always be avoided. Although a rare disease, it 
should be considered in the differential diagnosis of 
rapidly progressive dementia along with other disorders.
 
(FIGURE.1a DWI)
INCREASE UPTAKE IN CORTICAL AND BASAL 
GANGLION  
(FIGURE.1b, ADC)
LOW UPTAKE ON ADC IN THE FRONTOPARITAL 
CORTEX 
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